PBGENE-DMD NCT07429240 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

18

Planned enrollment

2029-11-01

Primary-completion proxy

Executive view

NCT07429240 evaluates PBGENE-DMD in Muscular Dystrophy, Duchenne. The disclosed sponsor is Precision BioSciences, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Incidence, severity, and causality of treatment-emergent adverse events and serious adverse events, assessed over From Dosing through Week 104.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07429240 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Muscular Dystrophy, Duchenne landscape. Drug & Asset MCP drug_fetch was queried for PBGENE-DMD, while Company & Deal Intelligence MCP organization_fetch was queried for Precision BioSciences, Inc..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07429240	PBGENE-DMD	Phase 1/2 / Recruiting	Precision BioSciences, Inc.	United States	Incidence, severity, and causality of treatment-emergent adverse events and serious adverse events From Dosing through Week 104	2029-11-01
NCT07475754	Rituximab	Not Applicable / Not yet recruiting	Peking Union Medical College Hospital	Geography not reported	The incidence of adverse events (AEs)； 1 year,	2026-05-30
NCT07347548	Tegacorat	Phase 1 / Completed	Grünenthal GmbH	France	Number of participants with Adverse Events (AEs) Through study completion, an average of 4 Weeks	2026-06-09
NCT07317063	Tegacorat	Phase 1 / Completed	Grünenthal GmbH	United States	Number of participants with Adverse Events Through study completion, an average of 7 Weeks	2026-01-06
NCT07287189	Forazapadin	Phase 2 / Recruiting	Satellos Bioscience, Inc.	Canada, Belgium, United States, Poland, United Kingdom, Serbia, Australia, Spain	Safety of SAT-3247 12 weeks in Part 1 and up to 12 months in part 2	2027-03-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07429240 is a Phase 1/2, recruiting study with 18 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Incidence, severity, and causality of treatment-emergent adverse events and serious adverse events” over “From Dosing through Week 104.” The retrieved endpoint description is: Adverse events and serious adverse events that occur or worsen after initiation of the investigational treatment.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Muscular Dystrophy, Duchenne. These records do not establish direct evidence for NCT07429240 unless the registration number matches.

Vamorolone for Duchenne Muscular Dystrophy

Phase 2; n=133; TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028) Source: https://pubmed.ncbi.nlm.nih.gov/42202243/

Family experience data with delandistrogene moxeparvovec gene therapy treatment for Duchenne muscular dystrophy.

Not Applicable; n=31; Improvement in at least one of the most impactful symptoms = 96.0 % Source: https://download.asgct.org/2026ASGCTAbstractPublication.pdf

Lowering pre-existing immunity to adeno-associated virus-based gene therapy: Pre treatment with imlifidase or plasmapheresis prior to administration of delandistrogene moxeparvove…

Phase 1; n=8; Micro-dystrophin Expression(Week 12) = 21.5 % ( 0.96 - 42.03); Micro-dystrophin Expression(Week 12) = 1.72 % ( 1.46 - 2.11) Source: https://download.asgct.org/2026ASGCTAbstractPublication.pdf

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “PBGENE-DMD.” The report therefore avoids inferring modality, target or global development stage from the name alone.

Precision BioSciences, Inc. is indexed in United States with the website https://precisionbiosciences.com. Develops technology to produce custom, genome-editing enzymes for human health and biological research The record lists 14 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether PBGENE-DMD is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07429240
Protocol source: https://clinicaltrials.gov/study/NCT07429240
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

PBGENE-DMD in Muscular Dystrophy, Duchenne is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence, severity, and causality of treatment-emergent adverse events and serious adverse events and 2029-11-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP